Clinical trials: Pancreas Cancer, Duct Cell Adenocarcinoma
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
PDAC - Pancreatic Ductal Adenocarcinoma
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.
- Trial name
- CASPER (NCT05853198)
- Testing
- ctDNA analysis
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT02178436
- Testing
- gemcitabine hydrochloride, Selinexor, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mohammed Najeeb Al Hallak
Pancreatic Ductal Adenocarcinoma
Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma
This study introduces a novel transfer learning-based contrastive language-image pretraining adapter (CLIP-adapter) model for predicting the tumor-stroma ratio (TSR) in pancreatic ductal adenocarcinoma (PDAC) using preoperative…
- Trial name
- NCT06302881
- Volunteers
- 207 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Neoplasm, Pancreas
Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)
In the current project we aim to study the oncological process of pancreatic cancer, from a perspective of the CSC-theory and in particular through the 'side population' (SP)-approach.
- Trial name
- NCT00936104
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Gasthuisberg
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Pancreas Cancer
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma
- Trial name
- AA NABPLAGEM (NCT03410030)
- Testing
- High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Adenocarcinoma Metastatic
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer.
- Trial name
- ParpVax2 (NCT06747845)
- Testing
- Niraparib, FOLFIRI, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
This phase II trial studies how well metformin hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin work in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01666730
- Testing
- metformin hydrochloride, oxaliplatin, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Pancreatic Adenocarcinoma
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after…
- Trial name
- GEMPAX (NCT03943667)
- Testing
- Gemcitabine, Paclitaxel
- Where
- 26 sites in France
- Volunteers
- 211 people
- Sponsor
- UNICANCER
Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
This phase II trial studies the effects of lenvatinib and pembrolizumab maintenance therapy in treating patients with pancreatic cancer that has spread to other places in the body (advanced) and cannot be removed by surgery…
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
- Trial name
- NCT04887805
- Testing
- Lenvatinib Mesylate, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Pancreatic Ductal Adenocarcinoma
Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.
The aim of this study is to determine whether para-aortic lymph nodes(No.16) should be included in the lymphadenectomy during the pancreatoduodenectomy in order to improve the long-term survival of patients with pancreatic head…
- Trial name
- NCT04115527
- Testing
- Extended Lymphadenectomy, Standard Lymphadenectomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Pancreatic Ductal Adenocarcinoma
DC Vaccine in Pancreatic Cancer
This research study is designed to evaluate the effects of a dendritic cell (kind of white blood cell) vaccine for pancreatic cancer.
- Trial name
- NCT03592888
- Testing
- mDC3/8-KRAS Vaccine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Pennsylvania
Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
This study examines heart rate monitoring variability for the early detection of pancreatic cancer. Pancreatic cancer is a very difficult disease to detect early.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
- Trial name
- NCT04400903
- Testing
- Activity Monitor, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
- Trial name
- SHARON (NCT04150042)
- Testing
- Melphalan, BCNU, Vitamin B12B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- General Oncology, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack…
- Trial name
- EMPIRE (NCT06843551)
- Testing
- Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Benjamin Spieler
CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
To explore the possibility to overcome CYP3A-mediated resistance to anticancer drugs in pancreatic cancer, we will investigate the pharmacokinetics, safety, tolerability, and efficacy of nanoparticle albumin-bound paclitaxel…
- Conditions
- CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- IntenSify (NCT05494866)
- Testing
- Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- German Cancer Research Center
Stage III Pancreatic Cancer
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC).
- Trial name
- DIRECT (NCT03899649)
- Testing
- SOC, NanoKnife System
- Where
- 14 sites in United States
- Volunteers
- 532 people
- Sponsor
- Angiodynamics, Inc.
Pancreas Adenocarcinoma
Analysis Of The Anxiety-Depressive Pattern, Quality Of Life And Assessment Of Personality in Patients With Pancreatic Ductal Adenocarcinoma (PACT24)
The aim of this study is the evaluation of psychological aspects, such as anxiety-depressive patterns, quality of life, personality and other psychopathological syndromes of patients who receive a diagnosis of pancreatic cancer…
- Trial name
- NCT04396093
- Testing
- psychological support
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Michele Reni